SEC Contract Filing

Filing Date: 2023-11-09

Document Content:
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>ntla-ex10_2.htm
<DESCRIPTION>EX-10.2
<TEXT>
<html>
 <head>
 <title>EX-10.2</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
 <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Exhibit 10.2</font></p>
 <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
 <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Execution Copy</font></p>
 <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Portions of this Exhibit have been redacted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed. Information that was omitted has been noted in this document with a placeholder identified by the mark &#x201c;[***]&#x201d;.</font></p>
 <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
 <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">THIRD AMENDMENT TO</font></p>
 <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">LICENSE AND COLLABORATION AGREEMENT</font></p>
 <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Third Amendment to the License and Collaboration Agreement (this &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Third Amendment</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), dated as of September 29, 2023 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Third Amendment Date</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), is entered into by and between REGENERON PHARMACEUTICALS, INC., a corporation organized under the laws of New York and having a principal place of business at 777 Old Saw Mill River Road, Tarrytown, NY 10591 (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Regeneron</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), and INTELLIA THERAPEUTICS, INC., a corporation organized under the laws of Delaware and having a principal place of business at 40 Erie Street, Suite 130, Cambridge, MA 02139 (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Intellia</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) (with each of Regeneron and Intellia referred to herein individually as a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Party</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; and collectively as the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Parties</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).</font></p>
 <p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">WHEREAS, Regeneron and Intellia entered into that certain License and Collaboration Agreement dated as of April 11, 2016 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Original Agreement</font><font style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), as amended by that certain Amendment 1